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The role of natural killer (NK) cells in the immune
response against vaccines is not fully understood.
Here, we examine the function of infiltrated NK cells
in the initiation of the inflammatory response trig-
gered by inactivated influenza virus vaccine in the
draining lymph node (LN). We observed that,
following vaccination, NK cells are recruited to the in-
terfollicular and medullary areas of the LN and
become activated by type I interferons (IFNs) pro-
duced by LN macrophages. The activation of NK
cells leads to their early production of IFNg, which
in turn regulates the recruitment of IL-6+ CD11b+
dendritic cells. Finally, we demonstrate that the
interleukin-6 (IL-6)-mediated inflammation is impor-
tant for the development of an effective humoral
response against influenza virus in the draining LN.INTRODUCTION
While contained inflammation enhances both humoral and
cellular adaptive immunity, uncontrolled or persistent inflamma-
tion has detrimental roles associated with reduced long-lived
memory cell formation and cellular exhaustion (Wherry, 2011).
Therefore, it is essential to better understand the mechanisms
that lead to the initiation of the inflammatory response following
vaccination.
Among the different types of inflammatorymolecules, type I in-
terferons (IFNs) are critical for the effective initiation of the inflam-
matory response and the generation of an antiviral state (Gabay
and Kushner, 1999). Additionally, they are also involved in the
activation of various immune cells such as dendritic cells (DCs)
and natural killer (NK) cells (Madera et al., 2016). In a previousCell Re
This is an open access article under the CC BY-Nstudy, we showed that lymph node macrophages (LNMs) are
one of themajor producers of type I IFNs at early times post influ-
enza vaccination. This mechanism is essential for the activation
of DCs and the regulation of the local humoral responses (Chat-
ziandreou et al., 2017). In addition, LNMs activate other innate
immune cells involved in the inflammatory process, such as NK
cells (Garcia et al., 2012).
NK cells play an important role in eliminating stressed and in-
fected cells without the need for prior sensitization (Vivier et al.,
2008). Moreover, they can directly recognize influenza virus via
receptor NKp46 (Mendelson et al., 2010). The absence of
NKp46 results in increasedmortality, highlighting the importance
of NK cell functions during influenza infection (Gazit et al., 2006).
Previous studies have stressed the role of NK cells as one of the
major producers of type II IFNs contributing to the activation of
T cells (Martı´n-Fontecha et al., 2004), macrophages (Mosser
and Edwards, 2008), DCs (Gerosa et al., 2002), and B cells
(Wilder et al., 1996). Despite the fact that NK cells have been
widely studied in various tissue and disease models, their role
in response to vaccination needs to be investigated.
RESULTS
NK Cells Are Recruited to the LN and Undergo Type I
IFN-Dependent Activation
To assess the involvement of NK cells in response to influenza
vaccination at early time points (0–24 h post vaccination; p.v.),
we investigated their recruitment to the draining LN after footpad
injection of ultraviolet inactivated influenza virus (UVPR8). We
observed a significant increase of total NK (Figure 1A) and
CD69+ and GranzymeB+ NK cell numbers (Figure 1B) at 12
and 24 h p.v., which correlated with an increase in their fluores-
cence intensity (Figure 1C). To assess NK cell recruitment, we
performed intravital two-photon microscopy (IV-2PM) in combi-
nation with epifluorescence time-lapse microscopy using Ncr1-
GFP mice (Gazit et al., 2006). We observed that NK cells wereports 26, 2307–2315, February 26, 2019 ª 2019 The Authors. 2307
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. NK Cells Get Recruited to the Popliteal Lymph Node at Early Times after Influenza Vaccination and Are Activated by Type I IFNs
(A and B) Flow cytometry showing total NK (A) and CD69+ and GranzymeB+ NK cell numbers (B) in the lymph node (LN) following vaccination at indicated time
points.
(C) Representative histograms of fluorescence intensity showing upregulation of CD69 and GranzymeB at 12 h post vaccination (p.v.) in comparison with non-
vaccinated controls. Median fluorescence intensity (MFI) values are indicated in parentheses.
(D) Snapshot from an epifluorescence time lapse (left) and two-photon microscopy (right) showing recruitment of NK cells (green) via blood vessels located in the
interfollicular area (IFA) of the LN at 12 h p.v.
(E) Confocal micrographs showing recruitment of NK cells in the IFA of LN from control (left) and vaccinated at 12 h p.v. (middle). The right graph shows the
quantification of the frequency of NK cell density in the medullary (Med), IFA, cortex, follicle (Fo), and subcapsular sinus (SCS) areas of the LN at indicated time
points.
(F) Flow cytometry showing frequency of CD69+ and GranzymeB+ NK cells after 12 h culture with UVPR8 and/or recombinant IFN-b compared with control
group.
(G) Representative histograms of fluorescence intensity rIFN-b-treated NK cells showing upregulation of CD69 and GranzymeB at 12 h p.v. compared to control
groups. MFIs are indicated in parentheses.
(H and I) Flow cytometry showing total CD69+ NK and GranzymeB+ NK cell numbers (H) and MFI values (I) at 12 h p.v. in LN of IFNAR/ and B6 mice.
In all figures, the presented data are representative of at least three independent experiments. Results are given as mean ± SD. ns, not significant, p > 0.05;
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.recruited via blood vessels (Figure 1D, left; Video S1) and accu-
mulated in the interfollicular area (IFA) of the LN (Figure 1D, right).
Additionally, using immunohistochemistry, we confirmed a sig-
nificant increase of these cells in the IFA of the LN at 12 h p.v.
(Figure 1E).
Next, we assessed the mechanism by which NK cells are re-
cruited to the LN by evaluating their number in IL1R/, inter-
feron-a/b receptor (IFNAR)/, and CXCR3/ animals. We
observed that IL1R/, IFNAR/, CXCR3/ showed no reduc-
tion in the total number of NK cells in the LN at 12 h p.v. (Figures
S1A and S1B). However, we observed that LN macrophages
were involved in the recruitment of the NK cells as their depletion
with clodronate liposomes (CLLs) significantly reduced the num-
ber of NK cells at 12 h p.v. (Figure S1C).2308 Cell Reports 26, 2307–2315, February 26, 2019NK cells can directly recognize hemagglutinin (HA) from influ-
enza virus via receptor NKp46 (Mandelboim et al., 2001). Thus,
we tested whether influenza vaccine can directly activate NK
cells in vitro. We cultured spleen-sorted NK cells with UVPR8
and observed a partial activation at 12 h post-culture, indicated
by a significant increase of CD69+ and GranzymeB+ NK cell fre-
quency (Figure 1F). Next, we cultured NK cells in the presence or
absence of recombinant IFN-b (rIFN-b). As expected, rIFN-b
alone was enough to increase the CD69+ and GranzymeB+ NK
cell frequency (Figure 1F), alongwith their expression (Figure 1G).
Moreover, we observed that the numbers of CD69+ and
GranzymeB+ NK cells decreased significantly in IFNAR/
mice at 12 h p.v. (Figure 1H) in concordance with the reduced
median fluorescence intensity (MFI) (Figure 1I). Finally, to
evaluate if the recruitment of activated NK cells at 12 h p.v. was
influenza specific, we designed a similar set of experiments us-
ing UV-inactivated DNA virus (vaccinia UVNYVAC-C). Interest-
ingly, we observed that the immunizationwith vaccinia promoted
a stronger NK cell recruitment at 12 h p.v. (Figure S1D). Addition-
ally, we observed a significant increase in the total number of
CD69+ and IFNg+ NK cells (Figures S1E and S1G, respectively)
but not in the MFI levels of CD69 and GranzymeB, which
were significantly reduced in animals vaccinated with vaccinia
compared with influenza (Figures S1E and S1F, respectively).
Subcapsular Sinus andMedullary Macrophages Interact
with NK Cells, Leading to Their Activation
To study the interaction between NK cells and LNMs, we per-
formed IV-2PM at 12 h p.v. on the popliteal LN of Ncr1-GFP
mice. We observed that NK cells interact with both subcapsular
sinus macrophages (SSMs; CD169+, F4/80; Figure 2A; Video
S2) and medullary macrophages (MMs; CD169+, F4/80+; Fig-
ure 2B, Video S2). To further evaluate these interactions, we
analyzed NK cell motion tracks in different regions of the LN.
We found that the preferential direction of NK cells was higher
in the IFA and the medulla compared to the subcapsular sinus
area (SCS; Figure 2C). Moreover, NK cells moved slower in the
medulla and SCS in comparison to the IFA, as indicated by the
reduction in their mean track speed (Figure 2D). Analysis of
the arrest coefficient, defined as the proportion of time in which
an NK cell moves slower than 2 mm/min, demonstrated that NK
cells arrested at a significantly higher rate in the medulla
compared to the SCS and the IFA (Figure 2E). To evaluate the
ability of LNMs to stimulate and activate NK cells in vivo, we elim-
inated LNMs by treatment with CLLs and analyzed the expres-
sion of CD11b by NK cells, as a marker of their maturation
(Kim et al., 2002). We observed that CLL-treated mice had a
significantly lower frequency of mature NK cells at 12 h p.v. in
comparison to the CLL-untreated group (Figure 2F). In addition,
the MFI levels of CD69 and GranzymeB in NK cells were signifi-
cantly reduced in the CLL-treated group compared to control
groups (Figure 2G), confirming the involvement of LNMs in NK
cell activation.
Involvement of NK Cells in the Early Inflammatory
Reaction Initiated by LNMs
Considering that NK cells are known to be one of the key players
in the type II IFN response (Vivier et al., 2008), we evaluated their
production of IFNg following influenza vaccination. The analysis
of LN extracts from the first 24 h following vaccination showed a
prominent peak in IFNg levels at 12 h p.v., followed by a striking
reduction at 24 h p.v. (Figure 3A). We observed that the number
IFNg+ NK cells peaked at 12 h p.v. (Figure 3B), correlating with
their frequency (Figure 3C). Moreover, we confirmed that NK
cells were the major producers of IFNg at this time (Figures
S2A and S2B) and pre-treatment with the aNK1.1 significantly
lowered the IFNg levels in the LN (Figure 3D). In addition,
confocal microscopy revealed that IFNg+ NK cells were located
in the IFA of the LN at 12 h p.v. (Figure 3E). Having identified the
effect of LNMs on NK cell activation, we observed a close inter-
action between IFNg+ cells and CD169+ macrophages at
12 h p.v. using IV-2PM imaging (Figure 3F). We assessed theinvolvement of LNMs in NK cell production of IFNg by depleting
LNMs with CLLs. We detected a significant decrease in IFNg+
NK cell numbers in animals lacking LNMs (Figure 3G), which
correlated with a significant reduction of secreted IFNg at
12 h p.v. (Figure 3H). We further evaluated the effect of IFNAR
on the production of IFNg by NK cells. We found that the total
number of IFNg+ NK cells (Figure 3I) and their MFI (Figure 3J)
were significantly reduced in IFNAR/ mice compared to the
control group. To further evaluate the role of NK cells in the in-
duction of the inflammatory response, we performed real-time
PCR on samples obtained from mice depleted of NK cells in
comparison to the control group. We observed that the tran-
scription levels of the inflammatory mediators IFNg and IL-6
were significantly elevated at 12 h p.v. in comparison to PBS
controls and NK-cell-depleted mice (Figures 3K and 3L). In
contrast, IL-18 and IL-1b levels were increased in mice lacking
NK cells (Figures 3M and 3N).
Early IFNg Secreted by NK Cells Is Important for the
Local Production of IL-6 in the Draining LN
To confirm that the reduction of IL-6 transcripts correlated with
its protein level, we measured the concentration of IL-6 in NK-
cell-depleted mice in comparison to the control group. We
confirmed that the absence of NK cells significantly reduced
the levels of IL-6 in the draining LN (Figure 4A). Interestingly,
we observed that the reduction of IL-6 was dependent on IFNg
(Figure 4A). Having shown the effects of LNMs and type I IFNs
on the regulation of IFNg production by NK cells, we examined
the levels of IL-6 in CD169DTR and IFNAR/ mice at 12 h p.v.
We observed a prominent reduction in the levels of IL-6 (Fig-
ure 4B) in animals lacking LNMs or type I IFN signaling. More-
over, in concordance with earlier studies (Hunter and Jones,
2015), we found that IL-6 production was dependent on
MyD88 signaling, as MyD88/ mice exhibited a complete
reduction in secreted IL-6 at 12 h p.v. (Figure 4C). Using flow cy-
tometry, we identifiedCD11b+DCs as themajor source of IL-6 at
12 h p.v. (Figures 4D and 4E). To investigate whether IFNg pro-
duced by NK cells is involved either in the proliferation or recruit-
ment of CD11b+ DCs, we checked their Ki-67 expression in the
presence or absence of NK cells at 12 h p.v. The absence of NK
cells did not affect DC proliferation (Figure S3A). However, we
measured a significant decrease in the number of IL-6+
CD11b+ DCs when we eliminated NK cells or blocked IFNg
signaling (Figures 4F and 4G, respectively). Additionally, we
could observe a decrease in the levels of different chemokines
known to be involved in the recruitment of DC precursors to
the LN (Figures S3B–S3D). Furthermore, to evaluate the capacity
of IFNg to directly stimulate IL-6 production by CD11b+ DCs, we
sorted CD11b+ splenic DCs and stimulated them with recombi-
nant IFNg or lipopolysaccharides (LPS) for 12 h. We saw that
IFNg could directly act on CD11b+ DCs to induce IL-6 secretion
(Figure S3E).
IL-6 Production Regulates Humoral Immunity in the
Draining LN
To determine whether additional production of IL-6 occurs at
later time points p.v., we examined the kinetics of IL-6 secretion
in the LN in response to UVPR8. We observed that the peaks ofCell Reports 26, 2307–2315, February 26, 2019 2309
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Figure 2. Subcapsular Sinus and Medullary Macrophages Interact Differently with NK, Leading to Their Activation
(A and B) Representative intravital two-photon micrograph showing close interactions between infiltrated NK cells with subcapsular sinus macrophages (SSMs)
(CD169-PE) (A) and medullary macrophages (MMs; CD169-PE, F4/80-AF647) (B) in the LN at 12 h p.v. Central panels represent the magnified dotted box. Right
panels demonstrated surface reconstruction of the zoomed images.
(C) Graphical representation of tracks with common origin showing preferential direction of NK cells in the interfollicular (IFA), medullary, and subcapsular sinus
area (SCS).
(D and E) Representative graphs showing track speed mean (D) and arrest coefficient (E) of NK cells in the indicated regions of the LN at 12 h p.v.
(F) Flow cytometric analysis of the frequency of CD11b+ and CD11b NK cells at 12 h p.v. in mice treated with/without CLLs compared with PBS controls.
(G) Flow cytometric quantification of CD69+ and GranzymeB+ NK cells at 12 h p.v. in mice treated with/without CLLs compared with PBS controls.
In all figures, the presented data are representative of at least three independent experiments. Results are given as mean ± SD. ns, p > 0.05; *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.IL-6 and IFNg occur within the first 24 h p.v. (Figures 5A and 5B,
respectively). Previous studies have demonstrated that IL-6 af-
fects B cell responses (Eto et al., 2011). Therefore, to examine
the involvement of IL-6 in the regulation of the local humoral re-
sponses to influenza vaccine, we neutralized the initial IL-6
production by administrating aIL-6 antibodies at the time of
vaccination. Using enzyme-linked immunospot assay (ELISPOT)
analysis, we observed a significant reduction in the number of2310 Cell Reports 26, 2307–2315, February 26, 2019influenza-specific antibody-secreting cells (ASCs) in the draining
LN at day 10 p.v. in IL-6-neutralized mice compared to untreated
controls (Figure 5C). Next, we tested whether the elimination of
NK cells or the absence of the interferon-g (IFNgR) would result
in a reduction of the local B cell responses to the virus. ELISPOT
analysis confirmed that the number of influenza-specific ASCs
were significantly reduced in both cases, compared to the
respective control groups (Figures 5D and 5E). Having validated
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Figure 3. Early Production of IFNg by NK Cells Is Dependent on the Type I IFN Response Initiated by LNMs
(A) ELISA showing IFNg in the LN at indicated time points p.v.
(B and C) Flow cytometric analysis of total IFNg+ NK cell numbers (B) and representative plots showing frequency of IFNg+ NK cells (C) at indicated time
points p.v.
(D) Cytoplex indicating IFNg in LN of aNK1.1-treated mice and control groups at 12 h p.v.
(E) Representative confocal micrograph of popliteal LN at 12 h p.v. (middle) showing IFNg+ cells (yellow), NK1.1+ cells (red), and IFNg-producing NK cells (merge)
located in the interfollicular area (IFA) of the LN. The left panel represent the control group, and the right panel indicates the zoomed area. Arrows indicate IFNg+
NK cells at 12 h p.v.
(F) Representative micrograph (left) and amplification (right) showing close interactions between IFNg+ cells and LNmacrophages (CD169-PE) at 12 h p.v. White
arrows indicate IFNg+ cells.
(G) Flow cytometry showing IFNg+ NK total numbers at 12 h p.v. in CLL-treated mice with respect to the control group.
(H) Cytoplex showing a reduction of IFNg levels in LN of CLL-treated mice at 12 h p.v. compared to control groups.
(legend continued on next page)
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(E) Flow cytometry showing the frequency of the IL-6+ cells in the LN.
(F and G) Flow cytometry indicating IL-6+ DC numbers at 12 h p.v. in LN of IFNgR/ (F) and anti-NK1.1-treated mice (G).
In all figures, the presented data are representative of at least three independent experiments. Results are given as mean ± SD. ns, p > 0.05; *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.the importance of IFNg and IL-6 in driving influenza-specific hu-
moral response, we investigated whether immunoglobulin G
(IgG) ASC reduction was due to impairment in B cell develop-
ment. We found that, while the level of IgG antibodies was
reduced, germinal center and plasma cell numbers were not
altered using neutralizing antibody treatments or when the type
II IFN signaling was blocked (IFNgR/) at 12 h p.v. (Figures
S4A and S4B).
DISCUSSION
In this study, we revealed that following influenza vaccination,
NK cells are preferentially located at the interfollicular and med-
ullary regions of the LN, which is in accordance with a previous
report (Baje´noff et al., 2006). Additionally, we demonstrated
that NK cell recruitment was independent of CXCR3 and depen-
dent on the presence LNMs. We also demonstrated that neither
type I IFNs nor IL-1a, produced by LNMs after vaccination (Chat-
ziandreou et al., 2017), were involved in the initial recruitment of(I and J) Flow cytometry of IFNg+ NK total numbers (I) and MFI values (J) in IFNA
(K–N) Quantitative real-time PCR analysis of cDNA from LN of mice treated with/
inflammatory molecules IFNg (K), IL-6 (L), IL-18 (M), and IL-1b (N).
In all figures, the presented data are representative of at least three independent e
****p < 0.0001.
2312 Cell Reports 26, 2307–2315, February 26, 2019NK cells. It is possible that the release of other danger signals
after the necrotic death of the LNMs (Chatziandreou et al.,
2017) could be involved in the recruitment of NK cells. Former
studies outlined that the activation of NK cells was associated
with their interaction with SSMs (Coombes et al., 2012; Garcia
et al., 2012). We show that MMs also interact with NK cells, form-
ing stable contacts in the medullary area. Considering the role of
type I IFNs on the functions of NK cells (Madera et al., 2016), we
confirmed that IFN signaling was necessary for the effective acti-
vation of NK cells. In a previous work, we reported that LNMs are
responsible for the initial production of type I IFNs following influ-
enza vaccination (Chatziandreou et al., 2017), which could
explain the close interactions of NK cells with the LNMs in these
areas. We also saw that recruitment of NK cells in the IFA,
together with their high speed, correlates with the presence of
IFNg+ cells in this region. In fact, we have formerly shown that
IFA are one of themajor sites for type I IFN production (Chatzian-
dreou et al., 2017). NK cells require several cytokines for full
maturation and to perform their effector functions (Brady et al.,R/ and control mice at 12 h p.v.
without anti NK1.1 compared to controls at 12 h p.v. testing the expression of
xperiments. Results are given as mean ± SD. ns, p > 0.05; *p < 0.05; **p < 0.01;
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Figure 5. NK-Regulated IL-6 Production Is
Involved in the Humoral Response against
Influenza Vaccine
(A and B) Time course showing the secreted levels
of the cytokines IL-6 (A) and IFNg (B) in the LN at 2,
6, 12, 24, 48, 72, 120, and 168 h p.v.
(C–E) ELISPOT analysis of IgG antibody-secreting
cells (ASCs) from UVPR8-vaccinated, aIL-6-
treated (C), aNK1.1-treated (D), and IFNgR/-
treated and aIFNg-treated (E) mice at 10 days p.v.
In all figures, the presented data are representative
of at least three independent experiments. Results
are given as mean ± SD. ns, p > 0.05; *p < 0.05;
**p < 0.01; ****p < 0.0001.2010). The decrease of NK cell maturation, activation, and pro-
duction of IFNg observed in the interferon-a/b receptor knockout
(IFNARKO)mice could be associatedwith the early production of
this cytokine by the LNMs. However, we cannot exclude the
contribution of other type-I-IFN-producing cells or alternative
factors that might affect NK cell effector functions.
It wasdemonstrated that innateCD8+Tcells are themajor pro-
ducers of early IFNg after administration of modified vaccinia vi-
rus (MVA) in the LN (Kastenm€uller et al., 2012). However, we
showed that following influenza vaccination, early production of
IFNg was mediated by NK cells. The observed discrepancy is
most likely related to the typeof pathogenstudied, since vaccina-
tion with another attenuated vaccinia virus (NYVAC-C) showed
that the magnitude of NK cell recruitment and their effector func-
tions were different in both models. Further, MVA was shown to
activate the inflammasome pathway, yet we could not detect
the expression of inflammasome-associated molecules in our
model. Interestingly, depletion of NK cells resulted in increased
transcription of IL-18 and IL-1b, which might be related with the
absence of IFNg as it was previously shown that IFNg promotes
the production of nitric oxide (NO) that prevents inflammasome
assembly (Mao et al., 2013; Mishra et al., 2013).
Previous studies have described that IFNg produced by NK
cells is essential for Th1 differentiation (Martı´n-Fontecha et al.,
2004). Prior to differentiation, CD4+ T cells need to be primed
by DCs in amulti-step process that requires at least a day (Mem-
pel et al., 2004). Although we observed an earlier release of IFNg
at 2 h p.v., the peak of IFNg secretion occurred at 12 h p.v.;
therefore, we discarded involvement of early IFNg in Th1 differ-
entiation. Instead, IFNg is also known to regulate the production
of various pro-inflammatory mediators, including tumor necrosis
factor alpha (TNF-a) (Donnelly et al., 1995), IL-12 (Libraty et al.,
1997), and IL-6 (Yi et al., 1996). In fact, the peaks of IFNg andCell RepoIL-6 secretion coincided, and both tran-
script and protein levels of IL-6 were
reduced in mice lacking NK cells. Further,
the 2 h IFNg release also correlated with
the presence of IL-6, confirming the inter-
dependence of the two cytokines. Impor-
tantly, neutralization of IFNg resulted in
decreased IL-6 secretion. It is important
to mention that a prominent decrease
in IL-6 levels observed in mice lackingtype I IFN receptors or LNMs suggests the presence of additional
factors in its regulation besides NK-cell-secreted IFNg. Among
the various types of IL-6-producing cells (Hunter and Jones,
2015), we revealed that CD11b+ DCs were the major source of
this cytokine at 12 h p.v. Moreover, we confirmed that IFNg
can act directly on a CD11b+ DC population to induce the secre-
tion of IL-6, as well as contributing to their recruitment. Also, in
accordance with previous studies (Naugler et al., 2007), the pro-
duction of IL-6 was dependent on viral recognition by Toll-like
receptors, as the absence of MyD88 signaling abolished its
secretion. Interestingly, we show that the lack of NK cells or
IFNg reduced the total number of IL-6-producing DCs, which
could be associated with poor monocyte differentiation into
DCs caused by the absence of IFNg (Goldszmid et al., 2012).
Moreover, proliferation of IL-6+ DCs was not affected by the
absence of NK cells, suggesting that the decrease is also not
related with the proliferative capacity of DCs. In fact, it is known
that IFNg is essential for DC homeostasis and activation (Akbar
et al., 1996). Therefore, it is possible that NK cell depletion af-
fects the reciprocal interactions between DCs and NK cells
required for DC homeostasis (Gerosa et al., 2002), leading to
the observed reduction in the number of DCs. Along this line,
depletion of NK cells resulted in decreased levels of macrophage
inflammatory protein (MIP)-1a, which is known to affect CD8a
CD11b+ DC maturation and activation in the LN (Bachmann
et al., 2006; Trifilo and Lane, 2004). Hence, it is probable that
NK cells are involved in activating DCs for IL-6 production along
with their maintenance in the LN at 12 h post influenza
vaccination.
We showed that the initial inflammatory peak directly affects
the humoral response to influenza virus, as blocking IL-6
reduced influenza-specific ASCs in the draining LN. The mecha-
nism by which IL-6 might influence this response is most likelyrts 26, 2307–2315, February 26, 2019 2313
related with the regulation of the follicular helper T cells (TFH) dif-
ferentiation and B cell activity as previously described (Choi
et al., 2013; Eto et al., 2011). Further, elimination of NK cells,
hence IFNg, may skew the overall inflammatory response, which
can affect the antibody isotype class switching, leading to a
reduction in IgG levels. It should also be noted that the depletion
method used here also depletes natural killer T (NKT) cells.
Although, we have shown that NKT cells are not involved in the
initial IFNg secretion and that we do not detect the presence of
IL-4 (Chatziandreou et al., 2017) in our vaccination model, it is
possible that elimination of NKT cells affects the overall B cell re-
sponses by other means.
In this work, we show that the type I IFN response generated
by LNMs is associated with the activation of NK cells, which in
turn produce IFNg leading to the recruitment of IL-6+ CD11b+
DCs. We demonstrated that both IL-6 and type II IFNs regulate
the influenza-specific local B cell responses.
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Bacterial and Virus Strains
Influenza A virus strain A/PR/8/34 Gonzalez et al., 2010 N/A
Vaccinia Virus Strain NYVAC-C Go´mez et al., 2007 N/A
Chemicals, Peptides, and Recombinant Proteins
Diphtheria Toxin from Corynebacterium diphtheriae Sigma Cat# D0564
Clodronate Liposomes (CLL) /PBS control liposomes Clodronateliposomes.com N/A
Zombie Aqua Fixable Viability Kit BioLegend Cat# 423101
Paraformaldehyde powder, 95% Sigma Cat# 158127-500G
Agarose, low gelling temperature Sigma Cat# A9414
Tween20 Sigma Cat# 9005-64-5
Triton-X Sigma Cat# 9002-93-1
Bovine Serum Albumine (BSA) Amresco Cat# 0332
Recombinant Mouse IFN-b Protein R&D Systems Cat# 8234-MB-010
Recombinant Mouse IFN-g Protein Abnova Cat# P4450
LPS RB-Ultrapure InvivoGen Cat# tlrl-eblps
DiD Thermo Fisher Cat# D7757
Ketamin Labatec Labatec Pharma Cat# 7680632310024
Rompun 2% (Xylazin) Bayer Cat# 6293841.00.00
3-Amino-9-ethylcarbazole Sigma-Aldrich Cat# A6926
Critical Commercial Assays
Intracellular Fixation & Permeabilization Buffer Set eBioscience Cat# 88-8824-00
LEGENDplex Mouse Proinflammatory Chemokine Panel (13-plex) BioLegend Cat# 740451
LEGENDplex Mouse Inflammation Panel (13-Plex) BioLegend Cat# 740150
Experimental Models: Organisms/Strains
C57BL/6 Janvier Labs RRID:MGI:5752053
IFNAR/ mice M€uller et al., 1994 N/A
CD169DTR mice Miyake et al., 2007 N/A
IFNgR/ mice Huang et al., 1993 N/A
Ncr1-GFP mice Gazit et al., 2006 N/A
OT-II TCR mice Barnden et al., 1998 N/A
IL-1R/ mice Glaccum et al., 1997 N/A
CXCR3/ mice Hancock et al., 2000 N/A
Oligonucleotides
IL-18 FW (50-GGTTCCATGCTTTCTGGACT-30) Microsynth N/A
IL-18 RV (50-GGCCAAGAGGAAGTGATTTG-30) Microsynth N/A
IL-6 FW (50-AGCCAGAGTCCTTCAGAG-30) Microsynth N/A
IL-6 RV (50-GGAGAGCATTGGAAATTG-30) Microsynth N/A
IFNg FW (50-GAGGAACTGGCAAAAGGATG-30) Microsynth N/A
IFNg RV (50-GCTGATGGCCTGATTGTCTT-30) Microsynth N/A
IL-1b FW (50-TGTTTTCCTCCTTGCCTCTG-30) Microsynth N/A
IL-1b RV (50-GCTGCCTAATGTCCCCTG-30) Microsynth N/A
GAPDH FW (50-ACATCATCCCTGCATCCACT-30) Microsynth N/A
GAPDH RV (50-AGATCCACGACGGACACATT-30) Microsynth N/A
Software and Algorithms
FlowJo software (TriStar , version 10.1) https://www.flowjo.com/ RRID:SCR_008520
FIJI software (Schindelin et al., 2012, version 1.48k) https://fiji.sc/ RRID:SCR_002285
Imaris software (Bitplane, version 8.4.2) http://www.bitplane.com/ RRID:SCR_007370
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LEGENDPlex software (Biolegend, version 7.0) https://www.biolegend.com/
legendplex/software
N/A
Prism software (GraphPad, version 4) https://www.graphpad.com/
scientific-software/prism/
RRID:SCR_002798
Adobe Illustrator (CC2018) https://www.adobe.com/ RRID:SCR_014198CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact,
Santiago F. Gonzalez (santiago.gonzalez@irb.usi.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Mice were bred in house or acquired from Janvier labs (C57BL/6). The following transgenic strains were used: IFNAR/ (M€uller et al.,
1994), CD169DTR (Miyake et al., 2007), IFNgR/ (Huang et al., 1993), Ncr1-GFP (Gazit et al., 2006), OT-II TCR (Barnden et al., 1998).
IL-1R/ (Glaccum et al., 1997), CXCR3/ (Hancock et al., 2000). All strains hadC56BL/6 background. For all the experiments young
and healthy female mice between 5-7 weeks of age were used. Mice were maintained in specific pathogen-free facilities at the IRB.
Experiments were performed in accordance with the Swiss Federal Veterinary Office guidelines and animal protocols were approved
by the local authorities.
In vitro NK cell culture and IFN-b stimulation
NK cells were sorted by FACSAria as CD3- NK1.1+ cells from spleens of C57BL/6 female mice and cultured at 5x105 cells/ml in com-
plete RPMI with/without rIFN-b 25 pg/well and/or UV-PR8 104 PFU/well in 96-well round bottom plates. 12 h later NK cells were sur-
face and intracellular labeled for FACS analysis.
In vitro CD11b+ DC culture and IFNg stimulation
Splenic CD11c+ DC were purified by magnetic cell separation according to manufacturer’s instructions (Miltenyi Biotec). Pre-en-
riched cells were sorted by FACSAria as CD11c+ MHC-II+ CD11b+ cells and 5x105 splenic CD11b+ DC were plated/well into a
96-well plate in complete RPMI alone or with recombinant IFNg (rIFNg) (10 mg/ml) or LPS (200 ng/ml) for 12 h. The supernatant
was then taken and analyzed for cytokine production.
METHOD DETAILS
Virus production, inactivation and labeling
Influenza virus strain A/PR/8/34 and vaccinia virus strain NYVAC-C (Go´mez et al., 2007) were used in this study. Influenza virus was
grown for 2 days in the allantoic cavity of 10-day embryonated chicken eggs. In order to remove cellular debris, allantoic fluid was
harvested and centrifuged at 3000 rpm for 30 min and virus was subsequently purified twice in a discontinuous sucrose gradient at
25,000 rpm for 90 min. The virus pellet was resuspended in PBS and aliquots were stored at 70C. Virus stocks were quantified by
plaque assays. The vaccinia virus NYVAC-C, provided by Prof. Mariano Esteban, (CNB,Madrid). To inactivate both viruses, viral sus-
pensions were placed under the UV lamp at a distance of 15 cm for 15min. For the labeling of UV-inactivated influenza virus, 50 mg/ml
of DiD was added to the viral suspension and incubated for 20 min at RT. After that, virus was subsequently purified by centrifugation
as mentioned before. DiD-UV-inactivated virus aliquots were stored at 70C.
Antigen administration and injections
106 plaque-forming units (PFU) of inactivated virus per footpad in a final volume of 10 mL were injected into anaesthetized mice at
different time points prior to LN collection. For macrophage depletion, mice were injected with 10 ml/footpad of CLL or PBS-contain-
ing liposomes (control) (Clodronateliposomes.org) at days 5 and 3 before vaccination. Macrophage depletion from CD169DTR mice
was established by intraperitoneal (i.p.) injection of 30 ng of diphtheria toxin (Sigma-Aldrich) per g of mouse a day before vaccination.
For NK cell depletion 300 mg of aNK1.1 (clone PK136; BioXCell) was administered i.p. (day-3) and intravenously (i.v.) (day-1) before
vaccine administration. IFNg blocking was performed by i.v. injection of 200 mg of aIFNg (clone XMG1.2, BioXCell) at the time of
vaccination. 4 h after vaccination 70 mg / footpad of aIFNgwas administered in a total volume of 10 ml. aIL-6 (clone ALF-161, BioXCell)
was administered i.v. at a dose of 200 mg/mice, as well as footpad at 120 mg/mice, at the time of vaccination. For in vivo labeling ofe3 Cell Reports 26, 2307–2315.e1–e5, February 26, 2019
cells, mice received 1 mg of fluorescently labeled aCD21/35, aF4/80 and aCD169/footpad (Biolegend), 3 to 5 h before image
acquisition.
Flow cytometry
Popliteal LNs were collected, disrupted with tweezers, and digested for 10 min at 37C in an enzyme mix composed of DNase I
(0.28 mg/ml, Amresco), dispase (1 U/mL, Corning), and collagenase P (0.5 mg/mL, Roche) in calcium- and magnesium-free PBS
(PBS-) followed by a stop solution composed of 2 mM EDTA (Sigma-Aldrich) and 2% heat-inactivated filter-sterilized fetal calf serum
(Thermo Fisher Scientific) in PBS- (Sigma-Aldrich). Fc receptors were blocked (aCD16/32, Biolegend) followed by surface staining
and analyzed by flow cytometry on an LSRFortessaTM (BD Biosciences). Where indicated, intracellular and/or nuclear staining
was performed according to the instructions (#88/8824/00, eBioscience, #00-5523-00, eBioscience). Dead cells were excluded us-
ing ZombieAcqua fixable viability dye (Biolegend) and data were analyzed using FlowJo software (TriStar Inc).
Immunohistology/microscopy
Mice were anesthetized with a mixture of ketamine (100mg/kg bodyweight, Parke Davis) and xylazine (10mg/kg bodyweight, Bayer)
and perfused with a fixative solution made of 10 mL of 0.05 M phosphate buffer containing 0.1 M L-lysine, 4% paraformaldehyde
(PFA), and 2 mg/mL NaIO4 at pH 7.4 (PLP). Popliteal LN were collected and further fixed in 4% PFA at 4C shaking for 4-6 h and
embedded in 5% low gelling agarose (Sigma-Aldrich). 50-100 mm sections were cut with Leica VT 1200S vibratome (Leica Microsys-
tems), blocked with proper sera and stained with the indicated antibodies in 0.05% Tween-20 in 0.5%BSA PBS- for two days at 4C
shaking (see antibody section). Immunofluorescence confocal microscopy was performed using a Leica TCS SP5 confocal micro-
scope (Leica Microsystems). Micrographs were acquired in sequential scans and merged to obtain a multicolor image. Images were
processed using Imaris software (Bitplane AG).
Cytoplex assay
LEGENDPlexTM assays (Mouse Proinflammatory Chemokine Panel and Mouse Inflammation Panel; Biolegend) were performed to
monitor cytokine/chemokine expression. Briefly, popliteal LNs were collected and carefully disrupted in 100 mL ice-cold phosphate
buffer, minimizing cell rupture. The suspension was centrifuged at 1,500 rpm for 5 min, and the supernatant was collected. 25 mL
supernatant was used for the protocol following the manufacturer’s instructions. Samples were analyzed by flow cytometry on an
LSRFortessa (BD Biosciences), and data were analyzed using LEGENDPlex software (BioLegend).
ELISPOT
For enzyme-linked immuno-spot assay (ELISPOT), on day 10 p.v., popliteal LNs were removed aseptically, disrupted, and passed
through a 40-mm cell strainer. 4 x105 cells were plated on UV-PR8-coated (107 PFU/mL) filter plates (MultiScreenHTS, Merck Milli-
pore) and incubated for 16 h at 37C. For detection, a biotin-conjugated aIgG was used, followed by avidin-Peroxidase (Sigma-
Aldrich). A developing solution consisting of 200mL 3-amino-9-ethylcarbazole (AEC) solution (Sigma-Aldrich) in 9mL sodium acetate
buffer containing 4 mL 30% H2O2 was subsequently added. Spots were read on a C.T.L. ELISPOT reader using ImmunoSpot
 5.1
software (Cellular Technology) and counted using ImageJ software.
Multiphoton microscopy and analysis
Deep tissue imaging was performed on a customized two-photon platform (TrimScope, LaVision BioTec). Two-photon probe exci-
tation and tissue second-harmonic generation (SHG) were obtained with a set of two tunable Ti:sapphire lasers (Chamaleon Ultra I,
Chamaleon Ultra II, Coherent) and an optical parametric oscillator that emits in the range of 1,010 to 1,340 nm (Cha-maleon Compact
OPO, Coherent), with output wavelength in the range of 690–1,080 nm.For the in vivo analysis of cell movement, two-photon micro-
graphs were acquired in full Z stacks of 50 mm every 30 s. To analyze NK cell motion quantitatively, manual tracking was used (Imaris
7.7.2, Bitplane). For the statistical analysis of cell migration, only track durations greater than 5 min were considered.
qPCR
Popliteal LNs were collected and disrupted in lysing matrix D 1.4-mm ceramic sphere tubes using FastPrep-24 tissue disruption (MP
Biomedicals), and RNA was isolated using an RNAeasy Mini kit (QIAGEN). A final amount of 0.5 mg of cDNA was synthesized using a
cDNA synthesis kit (Applied Biosystems) following the manufacturer’s recommendations. For qPCR reaction, SYBR Master Mix
(Applied Biosystems) was used, and samples were run on a 7900HT Fast Real-Time PCR System (Applied Biosystems). mRNA levels
were expressed relative to GAPDH expression. The Pfaffl method (Pfaffl, 2001) was used to calculate the relative expression of the
transcripts. Primers: IL-18 FW, 50-GGTTCCATGCTTTCTGGACT-30; and IL-18 RV, 50-GGCCAAGAGGAAGTGATTTG-30; IL-6 FW,
50-AGCCAGAGTCCTTCAGAG-30; IL-6 RV, 50-GGAGAGCATTGGAAATTG-30; IFNg FW, 50-GAGGAACTGGCAAAAGGATG-30; IFNg
RV, 50-GCTGATGGCCTGATTGTCTT-30 IL-1b FW, 50-TGTTTTCCTCCTTGCCTCTG-30; and IL-1b RV, 50-GCTGCCTAATGTCCC
CTG-30 GAPDH FW, 50-ACATCATCCCTGCATCCACT-30;GAPDH reverse, 50-AGATCCACGACGGACACATT-30.Cell Reports 26, 2307–2315.e1–e5, February 26, 2019 e4
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
Results were expressed as the mean ± standard deviation (SD). For statistical analysis Prism 4 (Graphpad Software, La Jolla, USA)
was used. Data was represented using Prism software. Group comparisons were assessed using nonparametric tests. All statistical
tests were two-tailed and statistical significance was defined as: * (p < 0.05), ** (p < 0.01), *** (p < 0.001) **** (p < 0.0001). The number
of times each experiment was repeated, and the number of animals used per experiment, are detailed in each figure.e5 Cell Reports 26, 2307–2315.e1–e5, February 26, 2019
